NewAmsterdam Pharma Company N.V. (NAMS)
NGM · Healthcare · Biotechnology
$22.80
+4.30%
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
Market Cap
$2.67B
Shares Outstanding
116.9M
P/S (TTM)
374x
Exchange
NGM
Currency
USD
About NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 348K | 32K | 3.0M | 3.7M |
| Operating Income | (55.1M) | (66.0M) | (58.4M) | (64.9M) |
| Net Income | (72.0M) | (74.9M) | (48.4M) | (64.1M) |
| Diluted EPS | $-0.61 | N/A | $-0.40 | $-0.55 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 102.7M | 14.1M | 45.6M | 22.5M |
| Operating Income | (3.6M) | (183.0M) | (176.3M) | (225.7M) |
| Net Income | (22.6M) | (176.9M) | (241.6M) | (203.8M) |
| Diluted EPS | $-1.19 | $-2.15 | $-2.56 | $-1.72 |